Skip to main content
OpenTrials
Completed

NCT Number: NCT02391298

An Online Self-Guided Meditation Course for Individuals With Multiple Sclerosis

The aim of this study is to examine whether meditation delivered by the internet improves mood and attention as well as increases levels of dopamine in individuals who have been diagnosed with Multiple Sclerosis.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Suffolk University

Boston, Massachusetts, 02114, United States

About this study

Multiple Sclerosis (MS) is thought to involve a chronic, autoimmune inflammatory process in which one's own immune system attacks the myelin sheath surrounding axons in the central nervous system. MS is associated with many symptoms that decrease one's quality of life including pain, spasticity, fatigue, bowel and bladder problems, dizziness, cognitive difficulties, and depression. There is currently no cure for MS.

Decreased levels of dopamine (DA) have been measured in the cerebrospinal fluid of those with the primary progressive type of MS. In individuals with the relapsing- remitting type of MS, dopamine levels showed a negative correlation to disease severity such that as dopamine levels decreased, disease severity increased. Additionally, many symptoms of MS are related to dopaminergic dysfunction and/or abnormalities in dopamine rich brain areas. Dopamine levels have been shown to increase via active meditation during PET imaging in long term meditators. Other studies have also linked dopamine release to meditation in the peripheral nervous system (via measures of a DA metabolite in blood plasma levels). It is not clear whether brief meditation training in naive participants may have similar effects. Whether meditation could enhance dopamine levels in patients with MS or meditation naïve individuals has not been studied. Both dopamine and mindfulness training have been linked to improved attention and emotion regulation. Research has also indicated that attentional failures and infrequent use of emotion regulation strategies predicted poorer quality of life in patients with MS. Thus, there is sufficient evidence to suggest that meditation can enhance attention, emotion regulation, and quality of life in individuals with MS and that dopamine may be a neurochemical mechanism for this change.

This study is an open trial pilot design with multiple assessments on measures of mindfulness, dopamine, inhibition, and emotion regulation. The primary goal of the current study is evaluate the efficacy of an internet based mindfulness program for individuals with MS. The investigators hypothesize that individuals with MS will show increased levels of mindfulness and improved emotion regulation and cognitive inhibition skills after the course. In addition, The investigators hypothesize that contrast sensitivity (a proxy measure of retinal dopamine levels) will increase after the course. A secondary goal of this study is to examine potential cognitive and neurochemical mechanisms of mindfulness in relation to emotion regulation. Specifically, the investigators propose to examine whether dopamine and cognitive inhibition mediate the relationship between mindfulness and improved emotion regulation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of Multiple Sclerosis
  • Must be available for 2 in person visits in Massachusetts

Exclusion criteria

  • Patients with psychosis.
  • Self-reported disorders of the central nervous system other than MS.
  • Participants currently engaged in weekly psychotherapy who are unable to reduce session to once per month for the duration of the study.
  • Sensorimotor limitations that would confound test results.
  • Daily meditation practice (current or during the last 3 months).
  • Medication changes in the past 3 months.
  • Participants who, due to their MS are medically unstable. This will be defined as anyone who is actively relapsing at the time of recruitment (or within the last two weeks), or who becomes symptomatic during training.

Treatment and study plan

Mindfulness Meditation

Behavioral

Primary outcomes

  1. The Stop Signal Test (SST)

    Time frame: Change from baseline of total correct responses on SST at 8 weeks

    Measure of Cognitive Inhibition

  2. The Freiburg Visual Acuity Test (FrACT)

    Time frame: Change from baseline of contrast sensitivity at 8 weeks

    Measure of Contrast Sensitivity

Secondary outcomes

  1. The Functional Assessment of Multiple Sclerosis (FAMS) Quality of Life Instrument

    Time frame: Baseline and 8 weeks

    self-report scale that assesses a range aspects of quality of life reported to be important by individuals with MS.

  2. Feedback Questionnaire

    Time frame: 8 weeks

    This self-report questionnaire was created in order to gather information regarding feasibility, acceptability, and general impressions of the program from participants.

  3. Mindful Attention Awareness Scale

    Time frame: Change from baseline in mindfulness skills at 8 weeks

    Self-report measure of levels of mindfulness

  4. Difficulties in Emotion Regulation Scale

    Time frame: Change from baseline in emotion regulation skills at 8 weeks

    self-report measure of emotional regulation skills

Sponsors and collaborators

Lead sponsor

Haley Duncanson

Other

Collaborators

  • Suffolk University

Registry information

Official study title

An Examination of Potential Neurochemical and Cognitive Mediators of the Relationship Between Mindfulness and Emotion Regulation in Individuals With Multiple Sclerosis: An Internet Based Self-Guided Pilot Study.

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
Mar 18, 2015
Registry last updated
Apr 26, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.